

# Josephine H Cox

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7804090/publications.pdf>

Version: 2024-02-01

97  
papers

4,929  
citations

87886  
38  
h-index

102480  
66  
g-index

99  
all docs

99  
docs citations

99  
times ranked

6207  
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance of International AIDS Vaccine Initiative African clinical research laboratories in standardised ELISpot and peripheral blood mononuclear cell processing in support of HIV vaccine clinical trials. <i>African Journal of Laboratory Medicine</i> , 2021, 10, 1056.	0.6	5
2	Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. <i>Lancet</i> , The, 2019, 393, 889-898.	13.7	99
3	Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. <i>Lancet HIV</i> , the, 2019, 6, e230-e239.	4.7	84
4	Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. <i>Lancet</i> , The, 2018, 391, 552-562.	13.7	235
5	Multiplexed FluoroSpot for the Analysis of Dengue Virus and Zika Virus Specific and Cross-Reactive Memory B Cells. <i>Journal of Immunology</i> , 2018, 201, 3804-3814.	0.8	18
6	Cryopreservation-related loss of antigen-specific IFN $\gamma$ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy. <i>Vaccine</i> , 2017, 35, 1898-1906.	3.8	40
7	Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans. <i>Journal of Virology</i> , 2017, 91, .	3.4	148
8	First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. <i>Journal of Infectious Diseases</i> , 2017, 215, 95-104.	4.0	38
9	Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition. <i>Aids</i> , 2016, 30, 1703-1712.	2.2	21
10	Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene. <i>Journal of Infectious Diseases</i> , 2016, 213, 1946-1954.	4.0	14
11	A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus Seronegative Men. <i>Journal of Infectious Diseases</i> , 2016, 214, 1341-1348.	4.0	44
12	Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16061.	4.1	39
13	Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention. <i>Annals of Internal Medicine</i> , 2016, 164, 313.	3.9	70
14	Assessment of Anti-HIV-1 Antibodies in Oral and Nasal Compartments of Volunteers From 3 Different Populations. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 130-137.	2.1	12
15	A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults. <i>PLoS ONE</i> , 2015, 10, e0125954.	2.5	31
16	A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults. <i>PLoS ONE</i> , 2015, 10, e0134287.	2.5	39
17	An influenza vaccine pill "can we swallow it?". <i>Lancet Infectious Diseases</i> , The, 2015, 15, 992-993.	9.1	0
18	Broad HIV Epitope Specificity and Viral Inhibition Induced by Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults. <i>PLoS ONE</i> , 2014, 9, e90378.	2.5	13

#	ARTICLE	IF	CITATIONS
19	Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1. <i>Molecular Therapy</i> , 2014, 22, 464-475.	8.2	188
20	Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in Africa. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 714-723.	3.3	8
21	Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials. <i>Journal of Immunological Methods</i> , 2014, 409, 107-116.	1.4	34
22	Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses. <i>Journal of Immunological Methods</i> , 2014, 409, 161-173.	1.4	28
23	The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN- $\gamma$ ELISpot) assay. <i>Journal of Immunological Methods</i> , 2014, 409, 31-43.	1.4	22
24	Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. <i>Journal of Clinical Investigation</i> , 2014, 124, 3147-3158.	8.2	168
25	Safety and Immunogenicity of DNA Prime and Modified Vaccinia Ankara Virus-HIV Subtype C Vaccine Boost in Healthy Adults. <i>Vaccine Journal</i> , 2013, 20, 397-408.	3.1	23
26	Safety and Immunogenicity of DNA and MVA HIV-1 Subtype C Vaccine Prime-Boost Regimens: A Phase I Randomised Trial in HIV-Uninfected Indian Volunteers. <i>PLoS ONE</i> , 2013, 8, e55831.	2.5	41
27	A DNA-Based Candidate HIV Vaccine Delivered via <i>In Vivo</i> Electroporation Induces CD4 Responses toward the $\pm 4127$ -Binding V2 Loop of HIV gp120 in Healthy Volunteers. <i>Vaccine Journal</i> , 2012, 19, 1557-1559.	3.1	36
28	Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge. <i>Vaccine</i> , 2012, 30, 1830-1840.	3.8	14
29	A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults. <i>PLoS ONE</i> , 2012, 7, e41936.	2.5	74
30	Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens. <i>PLoS ONE</i> , 2012, 7, e45840.	2.5	40
31	<i>In Vivo</i> Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers. <i>PLoS ONE</i> , 2011, 6, e19252.	2.5	160
32	A Double-Blind Randomized Phase I Clinical Trial Targeting ALVAC-HIV Vaccine to Human Dendritic Cells. <i>PLoS ONE</i> , 2011, 6, e24254.	2.5	8
33	Intra- and Inter-clade Cross-reactivity by HIV-1 Gag Specific T-Cells Reveals Exclusive and Commonly Targeted Regions: Implications for Current Vaccine Trials. <i>PLoS ONE</i> , 2011, 6, e26096.	2.5	10
34	Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine. <i>PLoS ONE</i> , 2010, 5, e8617.	2.5	41
35	Phase I Study of Safety and Immunogenicity of an Escherichia coli-Derived Recombinant Protective Antigen (rPA) Vaccine to Prevent Anthrax in Adults. <i>PLoS ONE</i> , 2010, 5, e13849.	2.5	35
36	Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate. <i>PLoS ONE</i> , 2010, 5, e13983.	2.5	72

#	ARTICLE	IF	CITATIONS
37	Quality Monitoring of HIV-1-Infected and Uninfected Peripheral Blood Mononuclear Cell Samples in a Resource-Limited Setting. <i>Vaccine Journal</i> , 2010, 17, 910-918.	3.1	20
38	A Phase 1/2 Study of a Multiclade HIV-1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV-1 Uninfected East Africans (RV 172). <i>Journal of Infectious Diseases</i> , 2010, 201, 600-607.	4.0	100
39	A Phase 2 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Vaccine Based on Adeno-Associated Virus. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 933-942.	1.1	36
40	Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine. <i>PLoS ONE</i> , 2010, 5, e8816.	2.5	47
41	Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa. <i>PLoS ONE</i> , 2010, 5, e12873.	2.5	86
42	Equivalence of ELISpot Assays Demonstrated between Major HIV Network Laboratories. <i>PLoS ONE</i> , 2010, 5, e14330.	2.5	47
43	Concordant Proficiency in Measurement of T-Cell Immunity in Human Immunodeficiency Virus Vaccine Clinical Trials by Peripheral Blood Mononuclear Cell and Enzyme-Linked Immunospot Assays in Laboratories from Three Continents. <i>Vaccine Journal</i> , 2009, 16, 147-155.	3.1	57
44	Evaluation and Recommendations on Good Clinical Laboratory Practice Guidelines for Phase III Clinical Trials. <i>PLoS Medicine</i> , 2009, 6, e1000067.	8.4	48
45	Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. <i>Vaccine</i> , 2009, 27, 4468-4474.	3.8	60
46	Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. <i>Vaccine</i> , 2009, 27, 5885-5895.	3.8	51
47	A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C-Modified Vaccinia Ankara Virus Vaccine Candidate in Indian Volunteers. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 1107-1116.	1.1	53
48	Broad Immunogenicity of a Multigene, Multiclade HIV-1 DNA Vaccine Boosted with Heterologous HIV-1 Recombinant Modified Vaccinia Virus Ankara. <i>Journal of Infectious Diseases</i> , 2008, 198, 1482-1490.	4.0	142
49	Peptide Impurities in Commercial Synthetic Peptides and Their Implications for Vaccine Trial Assessment. <i>Vaccine Journal</i> , 2008, 15, 267-276.	3.1	25
50	Magnitude, Breadth, and Functional Profile of T-Cell Responses during Human Immunodeficiency Virus Primary Infection with B and BF Viral Variants. <i>Journal of Virology</i> , 2008, 82, 2853-2866.	3.4	34
51	In a mixed subtype epidemic, the HIV-1 Gag-specific T-cell response is biased towards the infecting subtype. <i>Aids</i> , 2007, 21, 135-143.	2.2	25
52	A New Multi-clade DNA Prime/Recombinant MVA Boost Vaccine Induces Broad and High Levels of HIV-1-specific CD8+ T-cell and Humoral Responses in Mice. <i>Molecular Therapy</i> , 2007, 15, 1724-1733.	8.2	43
53	A High Viral Burden Predicts the Loss of CD8 T-Cell Responses Specific for Subdominant Gag Epitopes during Chronic Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2007, 81, 13809-13815.	3.4	13
54	Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. <i>Vaccine</i> , 2007, 25, 7737-7742.	3.8	23

#	ARTICLE	IF	CITATIONS
55	CD8 T-Cell Recognition of Multiple Epitopes within Specific Gag Regions Is Associated with Maintenance of a Low Steady-State Viremia in Human Immunodeficiency Virus Type 1-Seropositive Patients. <i>Journal of Virology</i> , 2007, 81, 2440-2448.	3.4	142
56	Measurement of cytokine release at the single cell level using the ELISPOT assay. <i>Methods</i> , 2006, 38, 274-282.	3.8	100
57	CTL epitope distribution patterns in the Gag and Nef proteins of HIV-1 from subtype A infected subjects in Kenya: use of multiple peptide sets increases the detectable breadth of the CTL response. <i>BMC Immunology</i> , 2006, 7, 8.	2.2	32
58	Circulating and Unique Recombinant Forms of HIV Type 1 Containing Subsubtype A2. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 695-702.	1.1	13
59	Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development. <i>Expert Review of Vaccines</i> , 2006, 5, 505-516.	4.4	34
60	Short Communication: Identification of a Novel HIV Type 1 CRF01_AE Cytotoxic T Lymphocyte (CTL) Epitope Restricted by an HLA-Cw0602 Allele and a Novel HLA-A0206/Peptide Restriction. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 1271-1282.	1.1	6
61	HIV-1 MN Env 15-mer peptides better detect HIV-1 specific CD8 T cell responses compared with consensus subtypes B and M group 15-mer peptides. <i>Aids</i> , 2005, 19, 1165-1172.	2.2	14
62	Standardization of cytokine flow cytometry assays. <i>BMC Immunology</i> , 2005, 6, 13.	2.2	203
63	Standardization and Validation Issues of the ELISPOT Assay. , 2005, 302, 051-086.		60
64	Results of an ELISPOT Proficiency Panel Conducted in 11 Laboratories Participating in International Human Immunodeficiency Virus Type 1 Vaccine Trials. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 68-81.	1.1	85
65	Immunodominance and Cross-Reactivity of B5703-Restricted CD8 T Lymphocytes from HIV Type 1 Subtype C-Infected Ethiopians. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 239-245.	1.1	10
66	Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDS VAXA® B/E prime-boost HIV-1 vaccine trial in Thailand. <i>Vaccine</i> , 2005, 23, 2522-2529.	3.8	93
67	Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4+ T cells to HIV-infected persons. <i>Clinical Immunology</i> , 2004, 111, 262-274.	3.2	25
68	HLA-A and -B allele expression and ability to develop anti-Gag cross-clade responses in subtype C HIV-1 infected Ethiopians. <i>Human Immunology</i> , 2004, 65, 648-659.	2.4	11
69	Longitudinal Study of Humoral Immune Responses in HIV Type 1 Subtype CRF01_AE (E)-Infected Thai Patients with Different Rates of Disease Progression. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 293-305.	1.1	20
70	Detection of high frequencies of HIV-1 cross-subtype reactive CD8 T lymphocytes in the peripheral blood of HIV-1-infected Kenyans. <i>Aids</i> , 2003, 17, 2149-2157.	2.2	17
71	Comprehensive Screening for Human Immunodeficiency Virus Type 1 Subtype-Specific CD8 Cytotoxic T Lymphocytes and Definition of Degenerate Epitopes Restricted by HLA-A0207 and -CW0304 Alleles. <i>Journal of Virology</i> , 2002, 76, 4971-4986.	3.4	39
72	Preparation of Clinical-Grade Recombinant Canarypox® Human Immunodeficiency Virus Vaccine® Loaded Human Dendritic Cells. <i>Journal of Infectious Diseases</i> , 2002, 186, 1242-1252.	4.0	26

#	ARTICLE	IF	CITATIONS
73	A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. Journal of Immunological Methods, 2002, 260, 157-172.	1.4	299
74	Selective Increases in HIV-Specific Neutralizing Antibody and Partial Reconstitution of Cellular Immune Responses during Prolonged, Successful Drug Therapy of HIV Infection. AIDS Research and Human Retroviruses, 2001, 17, 1021-1034.	1.1	26
75	Activating CTL precursors to reveal CTL function without skewing the repertoire by in vitro expansion. European Journal of Immunology, 2001, 31, 3557-3566.	2.9	23
76	Evaluation of Natural Killer Cell Activity. Molecular Biotechnology, 2000, 15, 147-154.	2.4	3
77	Identification of Highly Conserved and Broadly Cross-Reactive HIV Type 1 Cytotoxic T Lymphocyte Epitopes as Candidate Immunogens for Inclusion in Mycobacterium bovis BCG-Vectored HIV Vaccines. AIDS Research and Human Retroviruses, 2000, 16, 1433-1443.	1.1	49
78	HIV-1-Specific Antibody-Dependent Cellular Cytotoxicity (ADCC). , 1999, 17, 373-382.		8
79	Evaluation of Natural Killer Cell Activity. , 1999, 17, 383-390.		3
80	HIV-1-Specific Cytotoxic T-Cell Assays. , 1999, 17, 355-372.		3
81	Antibody-Dependent Cellular Cytotoxicity in HIV Type 1-Infected Patients Receiving VaxSyn, a Recombinant gp160 Envelope Vaccine. AIDS Research and Human Retroviruses, 1999, 15, 847-854.	1.1	9
82	Cross-clade Cytotoxic T Cell Response to Human Immunodeficiency Virus Type 1 Proteins among HLA Disparate North Americans and Thais. Journal of Infectious Diseases, 1998, 178, 1040-1046.	4.0	60
83	Desialylation of Peripheral Blood Mononuclear Cells Promotes Growth of HIV-1. Virology, 1997, 228, 123-131.	2.4	28
84	CD4+ T-Lymphocyte Lines Developed from HIV-1-Seropositive Patients Recognize Different Epitopes Within the V3 Loop. Journal of Acquired Immune Deficiency Syndromes, 1996, 11, 128-136.	0.3	7
85	Expression of Adenovirus E3/19K Protein Does Not Alter Mouse MHC Class I-Restricted Responses to Vaccinia Virus. Virology, 1994, 204, 558-562.	2.4	22
86	Nuclear Localization of a Double-Stranded RNA-Binding Protein Encoded by the Vaccinia Virus E3L Gene. Virology, 1993, 195, 732-744.	2.4	131
87	The multiple uses of viruses for studying antigen processing. Seminars in Virology, 1993, 4, 109-116.	3.9	8
88	Antigen Processing, Where Tumor-Specific T-Cell Responses Begin. Journal of Immunotherapy, 1993, 14, 202-208.	2.4	17
89	Differential pattern of T cell recognition of the 65-kDa mycobacterial antigen following immunization with the whole protein or peptides. European Journal of Immunology, 1989, 19, 1303-1310.	2.9	51
90	Orientation of epitopes influences the immunogenicity of synthetic peptide dimers. European Journal of Immunology, 1988, 18, 2015-2019.	2.9	92

#	ARTICLE	IF	CITATIONS
91	MECHANISM OF ACTION OF CYCLOSPORINE IN PREVENTING CARDIAC ALLOGRAFT REJECTION. Transplantation, 1987, 43, 338-342.	1.0	4
92	MECHANISM OF ACTION OF CYCLOSPORINE IN PREVENTING CARDIAC ALLOGRAFT REJECTION. Transplantation, 1987, 43, 343-345.	1.0	2
93	The 65kDa antigen of mycobacteriaâ€”a common bacterial protein?. Trends in Immunology, 1987, 8, 215-219.	7.5	161
94	The effects of cyclosporin on lymphocyte activation in a systemic graft-vs.-host reaction. European Journal of Immunology, 1985, 15, 1054-1059.	2.9	22
95	Lymphocyte traffic in pregnant or oestrogen stimulated rats. Journal of Reproductive Immunology, 1984, 6, 167-176.	1.9	13
96	The migration of lymphocytes across specialized vascular endothelium. Cellular Immunology, 1982, 66, 407-422.	3.0	95
97	Endpoint Assays in HIV-1 Vaccine Trials: Functioning in a Good Laboratory Practices Environment. , 0, , 239-275.		1